

Publikationen Prof. Girndt ab 2008

- 1 Girndt M: Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies. *Drugs Aging* 2008;25:823–840.
- 2 Girndt M: Zytomegalievirusinfektion nach Nierentransplantation. *Der Nephrologe* 2008;3:51–62.
- 3 Girndt M: Hygiene in Hämodialyseeinrichtungen. *Krankenhaushygiene up2date* 2008;3:305–318.
- 4 Heine GH, Ulrich C, Seibert E, Seiler S, Marell J, Reichart B, Krause M, Schlitt A, Köhler H, Girndt M: CD14(++)CD16(+) monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. *Kidney Int.* 2008;73:622–629.
- 5 Link A, Girndt M, Selejan S, Rbah R, Bohm M: Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot-study. *Crit Care* 2008;12:R111.
- 6 Seiler S, Schlitt A, Jiang XC, Ulrich C, Blankenberg S, Lackner KJ, Girndt M, Werdan K, Buerke M, Fliser D, Heine GH: Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V. *Nephrol Dial. Transplant.* 2008;23:3599–3604.
- 7 Sester M, Gartner BC, Girndt M, Sester U: Vaccination of the solid organ transplant recipient. *Transplant. Rev. (Orlando.)* 2008;22:274–284.
- 8 Ulrich C, Heine GH, Gerhart MK, Köhler H, Girndt M: Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. *Am J Transplant.* 2008;8:103–110.
- 9 Baus A, Fleischmann P, Girndt M, Haag-Weber M, Ludewig S, Pommer W, Vychytil A: Stellenwert der Peritonealdialyse bei der Behandlung der chronischen Herzinsuffizienz. *Nieren-Hochdruckkh.* 2009;38:395–398.
- 10 Ebelt H, Girndt M, Werdan K: Kardioreneraler "Cross talk" bei akuter Herzinsuffizienz - neue Therapieansätze? *Intensiv- und Notfallbehandlung* 2009;34:200–206.
- 11 Fiedler R, Jehle PM, Osten B, Dorligschaw O, Girndt M: Clinical nutrition scores are superior for the prognosis of haemodialysis patients compared to lab markers and bioelectrical impedance. *Nephrol. Dial. Transplant.* 2009;24:3812–3817.
- 12 Girndt M: Schutz vor der Übertragung viraler Infektionen in der Dialyse. *Spektrum der Nephrologie* 2009;22:15–23.
- 13 Girndt M: Epidemiologie, Diagnose und prognostische Bedeutung des akuten Nierenversagens. *Intensiv- und Notfallbehandlung* 2009;34:178–185.
- 14 Link A, Girndt M, Selejan S, Mathes A, Bohm M, Rensing H: Argatroban for anticoagulation in continuous renal replacement therapy*. *Crit Care Med.* 2009;37:105–110.
- 15 Rogacev KS, Ziegelin M, Ulrich C, Seiler S, Girndt M, Fliser D, Heine GH: Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcome. *Nephrol. Dial. Transplant.* 2009;24:3480–3486.
- 16 Diez C, Mohr P, Girndt M, Puehler T, Haneya A, Silber RE, Hofmann HS: Impact of Estimated Glomerular Filtration Rate According to Three Different Equations on Adverse Outcome After Valve and Combined Valve and Coronary Surgery. *ASAIO J* 2010;56:543–549.
- 17 Girndt M, Seibert E: Premature cardiovascular disease in chronic renal failure (CRF): A model for an advanced ageing process. *Exp. Gerontol.* 2010;45:797–800.
- 18 Girndt M, Litjens NH: Unmet needs and new promises in Hepatitis B vaccination for chronic kidney disease patients. *US Nephrology* 2010;5:15–19.

- 19 Herink AK, Kothe L, Girndt M, Keysser G: [Treatment options of acral ulcers in MCTD]. *Med. Klin. (Munich)* 2010;105:837–840.
- 20 Rogacev KS, Ulrich C, Blomer L, Hornof F, Oster K, Ziegelin M, Cremers B, Grenner Y, Geisel J, Schlitt A, Kohler H, Fliser D, Girndt M, Heine GH: Monocyte heterogeneity in obesity and subclinical atherosclerosis. *Eur. Heart J.* 2010;31:369–376.
- 21 Schneider A, Asmus G, Biggar P, Braun J, Dellanna F, Fiedler R, Galle J, Girndt M, Gondolf K, Hahn K, Koch M, Müller H, Rump LC, Vosskübler A, Winkler R, Wanner C: Hemoglobin cycling in hemodialysis patients. *Nephrology Reviews* 2010;2:1–5.
- 22 Ulrich C, Heine GH, Seibert E, Fliser D, Girndt M: Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease. *Nephrol Dial. Transplant.* 2010;25:2265–2272.
- 23 Weingartner O, Pinsdorf T, Rogacev KS, Blomer L, Grenner Y, Graber S, Ulrich C, Girndt M, Bohm M, Fliser D, Laufs U, Lutjohann D, Heine GH: The relationships of markers of cholesterol homeostasis with carotid intima-media thickness. *PLoS. One.* 2010;5:e13467.
- 24 Mohr P, Holzhausen H-J, Surow A, Girndt M, Markau S: Unklarer Serumkreatininanstieg bei einem 64-jährigen mann. *Der Nephrologe* 2010;5:520–524.
- 25 Girndt M, Mohr P, Markau S: Infektionen bei Nierenkranken: Prophylaxe und Therapie. *Nieren-Hochdruckkh.* 2010;39:409–415.
- 26 Brandenburg V, Fliser D, Fliser M, Floege J, Galle J, Girndt M, Haufe CC, Ketteler M, Wanner C: Praxisleitfaden zur Therapie des sHPT. *Der Nephrologe* 2011;6:274–276.
- 27 Fiedler R, Dorligjav O, Seibert E, Ulrich C, Markau S, Girndt M: Vitamin D Deficiency, Mortality, and Hospitalization in Hemodialysis Patients with or without Protein-Energy Wasting. *Nephron Clin Pract.* 2011;119:c220-c226.
- 28 Girndt M: Störungen des Elektrolytstoffwechsels. *Internist (Berl)* 2011;52:963–974.
- 29 Girndt M: [Dental care with local anesthesia: should the patient first discontinue ACE inhibitors?]. *MMW. Fortschr. Med.* 2011;153:20.
- 30 Girndt M: [Young patient with mild hypertension: angiotensin inhibitor or beta blocker?]. *MMW. Fortschr. Med.* 2011;153:17.
- 31 Henning C, Smuda M, Girndt M, Ulrich C, Glomb MA: Molecular basis of maillard amide-AGE formation in vivo. *J Biol. Chem.* 2011;286:44350–44356.
- 32 Nitschmann S, Markau S, Girndt M: [Optimal point of time for initiation of dialysis: IDEAL Study (Initiating Dialysis EARly and Late).]. *Internist (Berl)* 2011;52:336–338.
- 33 Ulrich C, Seibert E, Heine GH, Fliser D, Girndt M: Monocyte Angiotensin Converting Enzyme Expression May Be Associated with Atherosclerosis Rather than Arteriosclerosis in Hemodialysis Patients. *Clin. J. Am. Soc. Nephrol.* 2010;6:505–511.
- 34 Wagner S, Greco F, Doehn C, Hoda MR, Girndt M, Jocham D, Fornara P: Laparoscopic Versus Open Bilateral Nephrectomy in Transplant Recipients With Medication-Resistant Hypertension: Final Results of a Multicenter Study With 15 Years of Follow-up. *Transplant. Proc.* 2011;43:2557–2561.
- 35 Hohenadel H, Barth C, Exner M, Girndt M: Multiresistente Erreger in der ambulanten Dialyse: Was der Nephrologe wissen muss. *Der Nephrologe* 2011;6:177–190.
- 36 Fiedler R, Neugebauer F, Ulrich C, Wienke A, Gromann C, Storr M, Bohler T, Seibert E, Girndt M: Randomized Controlled Pilot Study of 2 Weeks' Treatment With High Cutoff Membrane for Hemodialysis Patients With Elevated C-Reactive Protein. *Artif. Organs* 2012;36:886–893.
- 37 Girndt M: [Clinical issues with uremia]. *Internist (Berl)* 2012;53:817–822.

- 38 Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, Shah VO, Balakrishnan VS, Guzman NJ, Girndt M, Periera BG, Feldman HI, Kusek JW, Joffe MM, Raj DS: Association between Albuminuria, Kidney Function, and Inflammatory Biomarker Profile. *Clin. J. Am. Soc. Nephrol.* 2012;7:1938–1946.
- 39 Pliquett RU, Mohr P, Mukhtar BE, Girndt M, Markau S: Plasmapheresis leading to remission of refractory nephrotic syndrome due to fibrillary glomerulonephritis: a case report. *J Med. Case. Reports.* 2012;6:116.
- 40 Pliquett RU, Girndt M: Hemodialysis vs. peritoneal dialysis in chronic heart failure: getting to the heart of the matter. *Kidney Int.* 2012;81:1274–1275.
- 41 Seibert E, Zhu F, Kuhlmann MK, Henson R, Oribello AM, Girndt M, Kotanko P, Levin NW: Slope analysis of blood volume and calf bioimpedance monitoring in hemodialysis patients. *Nephrol Dial. Transplant.* 2012;27:4430–4436.
- 42 Sterling KA, Eftekhari P, Girndt M, Kimmel PL, Raj DS: The immunoregulatory function of vitamin D: implications in chronic kidney disease. *Nat. Rev. Nephrol* 2012;8:403–412.
- 43 Girndt M: Geänderte Hygienegesetzgebung: Konsequenzen für die Dialyse. *Der Nephrologe* 2012;7:327–330.
- 44 Seibert E, Girndt M: Möglichkeiten zur Bestimmung des Optimalgewichts. *Der Nephrologe* 2012;7:114–120.
- 45 Nystrand R, Pitten FA, Wille B, Girndt M: Patienten mit Prionenerkrankungen an der Dialyse - eine Risikobewertung. *Krankenhaushyg Infektionsverhütung* 2012;34:101–107.
- 46 Girndt M: Diagnostik und Therapie von Elektrolytstörungen. *Dtsch. Med Wochenschr.* 2013;138:642–646.
- 47 Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT: Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. *Vaccine* 2013;31:5306–5313.
- 48 Seibert E, Müller SG, Fries P, Pattmöller J, Kuss O, Heine GH, Girndt M, Schneider G, Kotanko P, Zhu F, Levin NW, Kuhlmann MK: Calf Bioimpedance Spectroscopy for Determination of Dry Weight in Hemodialysis Patients: Effects on Hypertension and Left Ventricular Hypertrophy. *Kidney Blood Press Res.* 2013;37:58–67.
- 49 Seibert E, Heine GH, Ulrich C, Seiler S, Köhler H, Girndt M: Influence of Cholecalciferol Supplementation in Hemodialysis Patients on Monocyte Subsets: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Nephron Clin Pract.* 2013;123:209–219.
- 50 Beige J, Wendt R, Girndt M, Queck KH, Fiedler R, Jehle P: Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis. *BMJ Open.* 2014;4:e004275.
- 51 Ernst E, Girndt M, Pliquett RU: A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis. *BMC. Nephrol* 2014;15:28.
- 52 Girndt M: Hygiene in der Dialyse: was muss beachtet werden? *Der Nephrologe* 2014;9:131–138.
- 53 Henning C, Liehr K, Girndt M, Ulrich C, Glomb MA: Extending the Spectrum of alpha-Dicarbonyl Compounds in Vivo. *J Biol. Chem.* 2014;289:28676–28688.
- 54 Kaulen SA, Hubner C, Mieth J, Spindler K, Schwab R, Wimmer R, Wilhelm J, Amoury M, Girndt M, Werdan K, Ebel H: [Indocyanine green elimination for the evaluation of liver function: Prognostic value in patients with community-acquired sepsis.]. *Med. Klin. Intensivmed. Notfmed.* 2014;109:531–540.

- 55 Medenwald D, Girndt M, Loppnow H, Kluttig A, Nuding S, Tiller D, Thiery JJ, Greiser KH, Haerting J, Werdan K: Inflammation and Renal Function after a Four-Year Follow-Up in Subjects with Unimpaired Glomerular Filtration Rate: Results from the Observational, Population-Based CARLA Cohort. *PLoS. One.* 2014;9:e108427.
- 56 Pliquett RU, Radler D, Tamm A, Greinert D, Greinert R, Girndt M: Oliguric acute kidney injury as a main symptom of bradycardia and arteriosclerosis resolved by pacemaker implantation: a case report. *J Med. Case. Reports.* 2014;8:289.
- 57 Robinski M, Mau W, Lamprecht J, Krauth C, Girndt M: The Choice of Renal Replacement Therapy (CORETH) project: study design and methods. *Clin. Kidney J.* 2014;7:575–581.
- 58 Trojanowicz B, Ulrich C, Seibert E, Fiedler R, Girndt M: Uremic Conditions Drive Human Monocytes to Pro-Atherogenic Differentiation via an Angiotensin-Dependent Mechanism. *PLoS. One.* 2014;9:e102137.
- 59 Dopheide JF, Zeller GC, Kuhlmann M, Girndt M, Sester M, Sester U: Differentiation of Monocyte Derived Dendritic Cells in End Stage Renal Disease is Skewed Towards Accelerated Maturation. *Adv. Clin. Exp. Med.* 2015;24:257–266.
- 60 Girndt M: Bacteraemia in haemodialysis patients-not always *Staphylococcus aureus*. *Nephrol Dial. Transplant.* 2015;30:1055–1057.
- 61 Schneider SM, Malecki AK, Müller K, Schönfeld R, Girndt M, Mohr P, Hiss M, Kielstein H, Jager K, Kielstein JT: Effect of a single dialysis session on cognitive function in CKD5D patients: a prospective clinical study. *Nephrol Dial. Transplant.* 2015;30:1551–1559.
- 62 Girndt M, Fiedler R, Martus P, Pawlak M, Storr M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Zickler D, Schindler R: High cut-off dialysis in chronic hemodialysis patients. *Eur. J Clin Invest* 2015;45:1333–1340.
- 63 Funk I, Seibert E, Markau S, Girndt M: Clinical Course of Acute Kidney Injury in Elderly Individuals Above 80 Years. *Kidney Blood Press Res.* 2016;41:947–955.
- 64 Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A: Prävalenz der eingeschränkten Nierenfunktion. Bevölkerungsrepräsentative Studie von 2008-2011 zur Gesundheit Erwachsener in Deutschland (DEGS1). *Dtsch. Arztebl.* 2016;113:85–91.
- 65 Girndt M: Rationale Antibiotikatherapie bei chronischer Niereninsuffizienz. *Der Nephrologe* 2016;11:291–301.
- 66 Girndt M: Multiresistente Erreger. *Epidemiologie und Schutzmaßnahmen. Der Nephrologe* 2016;11:408–416.
- 67 Seibert E, Zohles K, Ulrich C, Kluttig A, Nuding S, Kors JA, Swenne CA, Werdan K, Fiedler R, Girndt M: Association between autonomic nervous dysfunction and cellular inflammation in end-stage renal disease. *BMC. Cardiovasc. Disord.* 2016;16:210.
- 68 Robinski M, Mau W, Wienke A, Girndt M: Shared decision-making in chronic kidney disease: A retrospection of recently initiated dialysis patients in Germany. *Patient. Educ. Couns.* 2016;99:562–570.
- 69 Plontke SK, Girndt M, Meisner C, Probst R, Oerlecke I, Richter M, Steighardt J, Dreier G, Weber A, Baumann I, Plossl S, Lohler J, Laszig R, Werner JA, Rahne T: [Multicenter trial for sudden hearing loss therapy - planning and concept]. *HNO* 2016;64:227–236.
- 70 Girndt M: Rationales Tumorscreening beim Dialysepatienten. *Der Nephrologe* 2016;11:34–40.
- 71 Robinski M, Mau W, Girndt M: Wann sind Peritoneal- und Hämodialysepatienten mit ihrer Behandlung zufrieden? *Der Nephrologe* 2016;11:211–212.

- 72 Zickler D, Willy K, Girndt M, Fiedler R, Martus P, Storr M, Schindler R: High cut-off dialysis in chronic haemodialysis patients reduces serum procalcific activity. *Nephrol Dial. Transplant.* 2016;31:1706–1712.
- 73 Robinski M, Strich F, Mau W, Girndt M: Validating a Patient-Reported Comorbidity Measure with Respect to Quality of Life in End-Stage Renal Disease. *PLoS. One.* 2016;11:e0157506.
- 74 Lehmann U, Riedel A, Hirche F, Brandsch C, Girndt M, Ulrich C, Seibert E, Henning C, Glomb MA, Dierkes J, Stangl GI: Vitamin D supplementation: Response and predictors of vitamin D metabolites - A randomized controlled trial. *Clin Nutr.* 2016;35:351–358.
- 75 Robinski M, Neumann D, Mau W, Wienke A, Girndt M: The Choice of Renal Replacement Therapy (CORETH) Project: Der psychosoziale Status in der Frühphase der Peritoneal- und Hämodialyse. *Nieren-Hochdruckkh.* 2016;45:194–201.
- 76 Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M: Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. *PLoS One* 2017;12:e0169024.
- 77 Hohmann C, Liehr K, Henning C, Fiedler R, Girndt M, Gebert M, Hulko M, Storr M, Glomb MA: Detection of Free Advanced Glycation End Products in Vivo during Hemodialysis. *J Agric Food Chem* 2017;65:930–937.
- 78 Neumann D, Robinski M, Mau W, Girndt M: Cognitive Testing in Patients with CKD: The Problem of Missing Cases. *Clin J Am Soc Nephrol* 2017;12:391–398.
- 79 Seibert E, Radler D, Ulrich C, Hanika S, Fiedler R, Girndt M: Serum klotho levels in acute kidney injury. *Clin Nephrol* 2017;87:173–179.
- 80 Robinski M, Mau W, Wienke A, Girndt M: The Choice of Renal Replacement Therapy (CORETH) project: dialysis patients' psychosocial characteristics and treatment satisfaction. *Nephrol Dial. Transplant.* 2017;32:315–324.
- 81 Trojanowicz B, Ulrich C, Kohler F, Bode V, Seibert E, Fiedler R, Girndt M: Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease. *Nephrol Dial. Transplant.* 2017;32:287–298.
- 82 Girndt M: Diagnostik und Therapie der chronischen Nierenerkrankung. *Internist (Berl)* 2017;58:243–256.
- 83 Seibert E, Lehmann U, Riedel A, Ulrich C, Hirche F, Brandsch C, Dierkes J, Girndt M, Stangl GI: Vitamin D supplementation does not modify cardiovascular risk profile of adults with inadequate vitamin D status. *Eur. J Nutr.* 2017;56:621–634.
- 84 Ulrich C, Trojanowicz B, Fiedler R, Kohler F, Wolf AF, Seibert E, Girndt M: Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis. *Nephron* 2017;135:231–241.
- 85 Seibert E, Müller SG, Pattmöller J, Kotanko P, Zhu F, Levin NW, Fiedler R, Kuhlmann MK, Girndt M: Calf Resistivity Values in Chronic Kidney Disease in a Caucasian Population. *Nephron* 2017;135:196–200.
- 86 Girndt M: Treating hepatitis C virus in patients with chronic renal failure. *Lancet Gastroenterol Hepatol* 2017;2:544–546.
- 87 Trojanowicz B, Ulrich C, Fiedler R, Storr M, Boehler T, Martus P, Pawlak M, Glomb MA, Henning C, Templin M, Werner K, Zickler D, Willy K, Schindler R, Girndt M: Impact of serum and dialysates obtained from chronic hemodialysis patients maintained on high cut-off membranes on inflammation profile in human THP-1 monocytes. *Hemodial Int* 2017;21:348–358.

- 88 Trocchi P, Girndt M, Scheidt-Nave C, Markau S, Stang A: Impact of the estimation equation for GFR on population-based prevalence estimates of kidney dysfunction. *BMC. Nephrol* 2017;18:341.
- 89 Zickler D, Luecht C, Willy K, Chen L, Witowski J, Girndt M, Fiedler R, Storr M, Kamhieh-Milz J, Schoon J, Geissler S, Ringdén O, Schindler R, Moll G, Dragun D, Catar R: Tumour necrosis factor- α in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression. *Nephrol Dial Transplant* 2018:574–585.
- 90 Girndt M: Metabolische Konsequenzen der Peritonealdialyse. *Aktuel Ernährungsmed* 2017;42:206–210.
- 91 Girndt M: Gesundheitsschutz in nephrologischen Krankenhausfachabteilungen. *Dialyse aktuell* 2017;21:494–498.
- 92 Neumann D, Mau W, Wienke A, Girndt M: Peritoneal dialysis is associated with better cognitive function than hemodialysis over a one-year course. *Kidney Int.* 2018:430–438.
- 93 Trojanowicz B, Ulrich C, Fiedler R, Martus P, Storr M, Boehler T, Werner K, Hulko M, Zickler D, Willy K, Schindler R, Girndt M: Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis. *Nephrol. Dial. Transplant.* 2018;33:34–43.
- 94 Willy K, Girndt M, Voelkl J, Fiedler R, Martus P, Storr M, Schindler R, Zickler D: Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro. *Blood Purif.* 2018:131–138.
- 95 Neumann D, Lamprecht J, Robinski M, Mau W, Girndt M: Social relationships and their impact on health-related outcomes in peritoneal versus haemodialysis patients: A prospective cohort study. *Nephrol Dial. Transplant.* 2018;98:235.
- 96 Girndt M: Katheterlock. *Nephrologe* 2018;13:118–120.
- 97 Klaus A, Baldensperger T, Fiedler R, Girndt M, Glomb MA: Influence of Transketolase-Catalyzed Reactions on the Formation of Glycolaldehyde and Glyoxal Specific Posttranslational Modifications under Physiological Conditions. *J Agric Food Chem* 2018:1498–1508.
- 98 Bhatnagar A, Pein U, Markau S, Weigand K, Fornara P, Girndt M, Seibert E: Influence of SPRINT Study Type Automated Office Blood Pressure Measurements on Hypertension Diagnosis in Kidney Transplant Patients. *Kidney Blood Press Res* 2018;43:310–317.
- 99 Pliquett RU, Noll A, Ibe R, Katz A, Ackmann C, Schreiber A, Girndt M: Hyperglycemia-related central pontine demyelination after a binge-eating attack in a patient with type-2 diabetes: A case report. *BMC Endocr Disord* 2018;18:18.
- 100 Henning C, Liehr K, Girndt M, Ulrich C, Glomb MA: Analysis and Chemistry of Novel Protein Oxidation Markers in Vivo. *J Agric Food Chem* 2018;66:4692–4701.
- 101 Linhart C, Ulrich C, Greinert D, Dambeck S, Wienke A, Girndt M, Pliquett RU: Systemic inflammation in acute cardiorenal syndrome: An observational pilot study. *ESC Heart Fail* 2018:920–930.
- 102 Hegner B, Schaub T, Janke D, Zickler D, Lange C, Girndt M, Jankowski J, Schindler R, Dragun D: Targeting proinflammatory cytokines ameliorates calcifying phenotype conversion of vascular progenitors under uremic conditions in vitro. *Sci Rep* 2018;8:12087.
- 103 Ewert L, Fischer A, Brandt S, Scurt FG, Philipsen L, Müller AJ, Girndt M, Zenclussen AC, Lindquist JA, Gorny X, Mertens PR: Cold shock Y-box binding protein-1 acetylation status in monocytes is associated with systemic inflammation and vascular damage. *Atherosclerosis* 2018;278:156–165.

- 104 Trojanowicz B, Imdahl T, Ulrich C, Fiedler R, Girndt M: Circulating miR-421 Targeting Leucocytic Angiotensin Converting Enzyme 2 Is Elevated in Patients with Chronic Kidney Disease. *Nephron* 2019;141:61–74.
- 105 Weigand K, Kawan F, Fischer K, Theil G, Mohammed N, Schumann A, Pein U, Fritz AK, Girndt M, Fornara P: Die Roboter assistierte Nierentransplantation: Technik und Besonderheiten. *Nieren-Hochdruckkh.* 2019;48:89–96.
- 106 Höpfner F, Jacob M, Ulrich C, Russ M, Simm A, Silber RE, Girndt M, Noutsias M, Werdan K, Schlitt A: Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease. The PHAMOS trial (Prospective Halle Monocytes Study). *Hellenic J Cardiol* 2019:311–321.
- 107 Markau S, Girndt M: Online-Hämodiafiltration im Prädilutionsmodus: einfach besser? *Nephrologe* 2019;14:377–378.
- 108 Pein U, Girndt M, Markau S, Fritz A, Breda A, Stöckle M, Mohammed N, Kawan F, Schumann A, Fornara P, Weigand K: Minimally invasive robotic versus conventional open living donor kidney transplantation. *World J Urol* 2020;38:795–802.
- 109 Pein U, Fritz A, Girndt M: Wartelistenpflege. *Urologe A* 2020;59:10–16.
- 110 Pliquett RU, Lübbert C, Schäfer C, Girndt M: Thrombotic microangiopathy and liver toxicity due to a combination therapy of leflunomide and methotrexate: a case report. *J Med Case Rep* 2020;14:26.
- 111 Ulrich C, Wilke A, Schleicher N, Girndt M, Fiedler R: Hypervolemia-Induced Immune Disturbances Do Not Involve IL-1 β but IL-6 and IL-10 Activation in Haemodialysis Patients. *Toxins (Basel)* 2020;12:159.
- 112 Girndt M: Hygiene und Infektionsprävention in Hämodialyseeinrichtungen. *Krankenh.yg.* up2date 2020;15:27–42.
- 113 Girndt M, Trojanowicz B, Ulrich C: Monocytes in Uremia. *Toxins (Basel)* 2020;12:E340.
- 114 Girndt M: Niereninsuffizienz und Infektionsanfälligkeit. *Nephrologe* 2020:268-271.
- 115 Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, Auer C von, Wendt R, Christ H, Brinkkoetter PT, Menne J: Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. *Blood Adv* 2020;4:3085–3092.
- 116 Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, Auer C von, Wendt R, Christ H, Brinkkoetter PT, Menne J: ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP. *Blood Adv* 2020;4:3093–3101.
- 117 Girndt M: Hygiene in der Nephrologie. *Nephrologe* 2020;30:1–10.
- 118 Pliquett RU, Schlump K, Wienke A, Bartling B, Noutsias M, Tamm A, Girndt M: Diabetes prevalence and outcomes in hospitalized cardiorenal-syndrome patients with and without hyponatremia. *BMC Nephrol* 2020;21:393.